ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ

ᱤᱸᱞᱤᱥ ᱞᱤᱸᱠ

https://or.wikipedia.org/wiki/Mirabegron

ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ(ᱤᱸᱞᱤᱥ ᱯᱟᱹᱨᱥᱤᱛᱮ Mirabegron, ᱢᱤᱫ ᱟᱹᱠᱷᱨᱤᱧ ᱧᱩᱛᱢ ᱢᱤᱨᱵᱮᱴᱨᱤᱠ/ Myrbetriq) ,ᱱᱚᱣᱟ ᱢᱤᱫ ᱨᱟᱱ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱪᱩᱰᱩᱛᱷᱩᱞᱤ ᱛᱤᱠᱪᱷᱟᱹᱨᱮ(overactive bladder) ᱵᱮᱵᱷᱟᱨᱚᱜᱼᱟ। ᱚᱠᱥᱤᱵᱭᱩᱴᱤᱱ (oxybutynin) ᱞᱮᱠᱟ ᱟᱱᱴᱤᱢᱚᱥᱠᱟᱨᱤᱱ ᱨᱟᱱ(antimuscarinic medication) ᱠᱷᱚᱱ ᱠᱚᱢᱜᱮᱠᱚ ᱯᱚᱥᱚᱸᱫᱼᱟ। ᱱᱚᱣᱟ ᱨᱟᱱ ᱢᱚᱪᱟ ᱨᱮᱠᱚ ᱮᱢᱚᱜᱼᱟ ।

ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ

ᱠᱞᱤᱱᱤᱠᱟᱞ ᱰᱮᱴᱟ
ᱵᱮᱯᱟᱨ ᱧᱩᱛᱩᱢᱠᱚ	Myrbetriq, Betanis, Betmiga, others
ᱮᱴᱟᱜ ᱧᱩᱛᱩᱢ	YM-178
ᱮ.ᱮᱭᱤᱪ.ᱮᱯᱷ.ᱮᱥ/ᱰᱨᱟᱜᱥ.ᱠᱚᱢ	Monograph
ᱰᱮᱴᱟ	EU EMA: yes US FDA: Mirabegron
ᱦᱚᱲᱢᱚᱜ ᱛᱷᱚᱠ	AU: B3 US: C (Risk not ruled out)
ᱵᱮᱵᱷᱟᱨ ᱨᱮᱱᱟᱜ ᱴᱷᱟᱶ	By mouth (tablets)
ᱮ.ᱴᱤ.ᱥᱤ ᱠᱳᱰ	G04BD12 (WHO)
ᱟᱹᱱᱟᱹᱨᱤ ᱦᱟᱞᱚᱛ
ᱟᱹᱱᱟᱹᱨᱤ ᱦᱟᱞᱚᱛ	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only ℞ (Prescription only)
ᱯᱷᱟᱨᱢᱟᱠᱳᱠᱟᱭᱱᱮᱴᱤᱠ ᱰᱮᱴᱟ
ᱵᱟᱭᱳᱭᱮᱵᱷᱮᱞᱮᱵᱷᱮᱞᱤᱴᱤ	29–35%
ᱯᱨᱳᱴᱤᱱ ᱛᱚᱱᱚᱞ	71%
ᱢᱮᱴᱟᱵᱳᱞᱤᱡᱚᱢ	Hepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase
ᱵᱟᱹᱜᱤ ᱟᱫᱷᱟ-ᱡᱤᱭᱚᱱ	50 hours
ᱨᱟᱪᱟᱥᱮᱫ	Urine (55%), faeces (34%)
ᱩᱯᱨᱩᱢᱤᱭᱟᱹ
ᱟᱭ.ᱭᱩ.ᱯᱤ.ᱮ.ᱥᱤ ᱧᱩᱛᱩᱢ 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
ᱥᱤ.ᱮ.ᱮᱥ ᱱᱚᱢᱵᱚᱨ	223673-61-8
ᱯᱟᱵᱽᱠᱮᱢ ᱥᱤ.ᱟᱭ.ᱰᱤ	9865528
ᱠᱮᱢᱥᱯᱟᱭᱰᱟᱨ	8041219
ECHA InfoCard	100.226.392
Chemical and physical data
ᱯᱷᱚᱨᱢᱩᱞᱟ	C21H24N4O2S
ᱢᱤᱞᱟᱨ ᱢᱟᱥ	396.506 g/mol g·mol−1
ᱛᱷᱨᱤᱰᱤ ᱢᱚᱰᱮᱞ (ᱡᱮ.ᱮᱥ.ᱢᱳᱞ)	Interactive image
ᱮᱥ.ᱮᱢ.ᱟᱭ.ᱮᱞ.ᱤ.ᱮᱥ O=C(Nc1ccc(cc1)CCNC[C@H](O)c2ccccc2)Cc3nc(sc3)N
ᱟᱭ.ᱮᱱ.ᱥᱤ.ᱮᱭᱤᱪ.ᱮᱞ InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1 Key:PBAPPPCECJKMCM-IBGZPJMESA-N

ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ ᱨᱮᱱᱟᱜ ᱚᱨᱥᱚᱝ ᱛᱮ ᱥᱚᱠᱛᱚ ᱢᱟᱭᱟᱢ ᱪᱟᱯ , ᱵᱚᱦᱚᱜ ᱦᱟᱹᱥᱩ, ᱪᱩᱰᱩ ᱱᱟᱞᱟ ᱜᱷᱟᱣ ᱠᱚ ᱦᱩᱭ ᱫᱟᱲᱟ ᱦᱟᱜᱼᱟ । ᱱᱚᱣᱟ ᱵᱟᱫ ᱠᱟᱛᱮ ᱟᱧᱤᱭᱳᱭᱤᱰᱤᱢᱟ, ᱚᱦᱤᱥᱟᱹᱵ ᱡᱤᱣᱤᱪᱟᱹᱞᱩ irregular heart rate ᱟᱨ ᱭᱩᱨᱤᱱᱟᱨᱤ ᱨᱤᱴᱮᱱᱥᱚᱱ ᱦᱩᱭᱫᱟᱲᱮ ᱦᱟᱜᱼᱟ । ᱱᱚᱣᱟ ᱵᱤᱴᱟᱼ᱓ ᱟᱰᱨᱮᱱᱡᱤᱠ ᱨᱤᱥᱮᱯᱴᱚᱨᱼᱮ (β₃ adrenergic receptor) ᱪᱮᱸᱜᱷᱟ ᱦᱚᱪᱚ ᱠᱷᱟᱹᱛᱤᱨ ᱪᱩᱰᱩᱛᱷᱩᱞᱤ (bladder) ᱚᱪᱚᱲᱚᱜᱼᱟ ।

ᱰᱟᱠᱛᱚᱨᱤ ᱵᱮᱵᱷᱟᱨ ᱞᱟᱹᱜᱤᱫ ᱒᱐᱑᱒ ᱥᱟᱞ ᱨᱮ ᱭᱩ ᱮᱥ ᱮ ᱱᱚᱣᱟ ᱨᱟᱱ ᱢᱟᱱᱚᱛ ᱮ ᱮᱢ ᱞᱮᱫ ᱛᱟᱦᱮᱸᱫ । ᱒᱐᱑᱙ ᱥᱟᱞ ᱨᱮ ᱭᱩᱱᱟᱭᱴᱮᱰ ᱠᱤᱝᱰᱚᱢᱨᱮ (United Kingdom) ᱮᱱᱮᱪᱮᱥ (NHS) ᱢᱤᱫ ᱪᱟᱸᱫᱚ ᱨᱮᱱᱟᱜ ᱰᱳᱡ ᱯᱤᱪᱷᱟᱹ ᱒᱙ ᱯᱟᱶᱰ ᱞᱮᱠᱟ ᱠᱷᱚᱨᱚᱪ ᱦᱩᱭ ᱟᱭ ᱠᱟᱱ ᱛᱟᱦᱮᱸᱫ । ᱭᱩ ᱮᱥ ᱮ ᱨᱮ ᱢᱤᱫ ᱪᱟᱸᱫᱚ ᱨᱮ ᱱᱚᱣᱟ ᱨᱮᱱᱟᱜ ᱦᱳᱞᱥᱮᱞ ᱫᱟᱢ ᱓᱖᱙ ᱟᱢᱮᱨᱤᱠᱟ ᱰᱚᱞᱟᱨ ᱠᱟᱱᱟ । ᱒᱐᱑᱖ ᱥᱟᱞ ᱨᱮ ᱱᱚᱣᱟ ᱨᱟᱱ ᱑ᱱᱤᱭᱩᱛ ᱠᱷᱚᱱ ᱡᱟᱹᱥᱛᱤ ᱯᱨᱮᱥᱠᱨᱤᱯᱥᱚᱱ ᱞᱮᱱ ᱠᱷᱟᱹᱛᱤᱨ ᱡᱟᱹᱥᱛᱤ ᱯᱨᱮᱥᱠᱨᱤᱯᱥᱚᱱ ᱦᱟᱠᱟᱱ ᱨᱟᱱ ᱨᱮᱱᱟᱜ ᱛᱟᱹᱞᱠᱟᱹᱨᱮ ᱒᱖᱓ ᱟᱱᱟᱜ ᱴᱷᱟᱶ ᱮ ᱟᱢᱮᱴ ᱞᱮᱫᱼᱟ ।

ᱵᱟᱦᱨᱮ ᱡᱚᱱᱚᱲ

• Sacco, E.; Bientinesi, R. (2012). "Mirabegron: A review of recent data and its prospects in the management of overactive bladder". Therapeutic Advances in Urology. 4 (6): 315–24. doi:10.1177/1756287212457114. PMC 3491758. PMID 23205058.